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Peptidoglycan (PG) is an essential net-like macromolecule that surrounds bacteria, gives
them their shape, and protects them against their own high osmotic pressure. PG synthe-
sis inhibition leads to bacterial cell lysis, making it an important target for many antibiotics.
The final two reactions in PG synthesis are performed by penicillin-binding proteins (PBPs).
Their glycosyltransferase (GT) activity uses the lipid II precursor to synthesize glycan chains
and their transpeptidase (TP) activity catalyzes the cross-linking of two glycan chains via the
peptide side chains. Inhibition of either of these two reactions leads to bacterial cell death.
β-lactam antibiotics target the transpeptidation reaction while antibiotic therapy based on
inhibition of the GTs remains to be developed. Ongoing research is trying to fill this gap
by studying the interactions of GTs with inhibitors and substrate mimics and utilizing the
latter as templates for the design of new antibiotics. In this review we present an updated
overview on the GTs and describe the structure-activity relationship of recently developed
synthetic ligands.
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PEPTIDOGLYCAN BIOSYNTHESIS
The emergence of multidrug-resistant bacteria causes major pub-
lic health problems, particularly in medical facilities where the
lack of efficient antibiotics could jeopardize the advances made in
the treatment of many diseases. New efficient antibiotics against
multidrug-resistant strains are urgently needed to counter this
worrying situation.
Peptidoglycan (PG) is an essential net-like macromolecule that
surrounds most bacteria, gives them their shape, and protects them
against their own high osmotic pressure (Vollmer et al., 2008).
PG is assembled by the membrane-bound PG synthases [glyco-
syltransferases (GTs) and transpeptidases (TPs)]. Its degradation
or the inhibition of its synthesis leads to bacterial lysis and cell
death. This makes PG a successful target for many antibiotics such
as molecules of the penicillin family, which covalently bind to
the TP active sites and block PG cross-linking. As a consequence,
these enzymes are known as penicillin-binding proteins (PBPs)
(Sauvage et al., 2008). The immediate precursor of PG is lipid
II, which consists of the disaccharide N -acetylglucosamine (Glc-
NAc) and N -acetylmuramic acid (MurNAc)-peptide attached to
the membrane-bound undecaprenyl lipid carrier via a pyrophos-
phate group (Figure 1). Lipid II is synthesized inside the cell by
a series of cytoplasmic and membrane-associated proteins (Bar-
reteau et al., 2008). It is flipped across the cytoplasmic membrane
by the flippases of the SEDS family such as RodA, FtsW, and
SpoVE involved in shape, elongation, division, and sporulation
(Mohammadi et al., 2011). Once in the membrane outer leaflet,
the disaccharide peptide moiety of lipid II is polymerized by the
GTs, forming the nascent PG which is immediately incorporated
into the preexisting PG layer by the TPs via the peptide stems
(Vollmer et al., 2008).
A single bacterial cell contains several PBPs, among which are
bifunctional GT/TP class A PBPs and monofunctional TP class
B PBPs. Monofunctional GTs also exist in a few bacterial species
(Sauvage et al., 2008). Despite their apparent redundancy PBPs are
highly specialized proteins and their in vivo function is dictated by
the morphogenetic network of partner proteins within which they
operate rather than by the reaction they catalyze (den Blaauwen
et al., 2008). As occurs with the inhibition of the PBP TP activity
by β-lactam antibiotics, GT inhibition will block the PG synthetic
machinery and lead to bacterial cell lysis.
THE GLYCOSYLTRANSFERASES: SUBSTRATES, STRUCTURE,
AND MECHANISM
The essential function of GTs is conserved among most bacterial
species and has no eukaryotic counterparts. These characteris-
tics and GTs’ localization on the outer face of the cytoplasmic
membrane make them attractive and easily accessible targets for
antibacterial compounds.
In the last decade our understanding of the GT reaction
(Figure 1) at the enzymatic and structural levels has improved
significantly. The characterization of several GT enzymes has been
made possible thanks to the development of methods for the syn-
thesis or isolation of labeled (fluorescent or radioactive) lipid II
and lipid IV (lipid-linked tetrasaccharide) substrates and analogs
(Schwartz et al., 2001; VanNieuwenhze et al., 2001, 2002; Ye et al.,
2001; Breukink et al., 2003; Zhang et al., 2007; Gampe et al., 2011;
Shih et al., 2011). This has allowed the development of assays
to estimate their activity, such as the continuous fluorescent assay
(Schwartz et al., 2002), which could be adapted to a microtiter plate
format to screen for assay conditions and GT inhibitors (Offant
et al., 2010; Derouaux et al., 2011). Methods for the synthesis of
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FIGURE 1 | Mechanism of glycan chain polymerization by a
glycosyltransferase.
lipid IV substrate and higher oligosaccharides of MurNAc-GlcNAc
have been described recently (Zhang et al., 2007; Gampe et al.,
2011; Shih et al., 2011). They have provided a better understand-
ing of the interaction between the GTs and their natural substrates
and will facilitate the study of inhibitor specificity as well as the
design of substrate-based inhibitors of the GTs.
Moenomycin is a specific inhibitor of the GTs and has been
used to study their properties (Welzel, 2005). Its complete syn-
thesis has been achieved; the synthetic genes have been identified
and expressed in heterologous strains to produce defined frag-
ments of the molecule (Taylor et al., 2006; Ostash et al., 2007).
Several analogs have been prepared and characterized, including
fluorescently labeled moenomycin, which was used to develop a
high-throughput screening assay (Welzel, 2005; Adachi et al., 2006;
Cheng et al., 2008).
Efforts in protein expression and purification from different
bacterial species have allowed the determination of the crystal
structures of GTs both in the apo form and in complex with
moenomycin or analogs (Lovering et al., 2007; Yuan et al., 2007;
Heaslet et al., 2009; Sung et al., 2009). The sequences and struc-
tures of the GTs are highly conserved. They all have five conserved
motifs in their sequences, containing residues important for the
interaction with the substrates and for the activity of the enzyme
(Terrak et al., 2008). The 3D structures show that the proteins
from different species have similar folds composed mainly of α-
helices and similar binding modes to moenomycin with only a
few variations. The GT domain is divided into a head subdomain
with similarities to the phage λ lysozyme, a hydrolytic enzyme
that catalyzes the breakdown of the PG polymer, and a so-called
jaw domain, specific to the GT51 family. The jaw domain con-
tains a hydrophobic region partly embedded in the cytoplasmic
membrane that facilitates access to the membrane-bound lipid II
substrate. The interface between these two subdomains harbors
the enzymatic cavity and can be divided into two substrate bind-
ing sites: a donor site for the lipid-bound growing glycan chain
and an acceptor site for lipid II (Figure 2). They are separated by
a mobile region, which has only been well defined in the Staphy-
lococcus aureus PBP2 and MtgA (monofunctional GT) structures
(Lovering et al., 2008; Heaslet et al., 2009), and has been proposed
to play a role in the catalytic mechanism. Interestingly, Escherichia
coli PBP1b and S. aureus MtgA have been crystallized with their
transmembrane (TM) helix (66–96 in PBP1b) (Sung et al., 2009;
Huang et al., 2012). The structure of PBP1b shows that the TM
residues 83–88 interact with residues 292–296 of the GT domain.
Although no interaction between moenomycin and the TM seg-
ment has been observed in the crystal structure of the complex,
moenomycin has been found to bind with higher affinity to the
full-length E. coli PBP1b than to the protein without the TM seg-
ment (Cheng et al., 2008). The full-length PBP1b and MtgA with
TM segments showed higher activity than the truncated forms
(Sung et al., 2009; Huang et al., 2012) and the TM of Streptococcus
pneumoniae PBP2a was found to influence the glycan chain length
(Helassa et al., 2012). These reports suggest that the TM may play a
role in substrate and moenomycin binding and in the GT reaction.
The direction of the elongation of the glycan chain by the GTs
has been a matter of debate for a long time. It is now established
that this occurs by the addition of disaccharide subunits to the
anomeric (reducing) end of the growing chain (Fraipont et al.,
2006; Perlstein et al., 2007) (Figure 1). The reaction catalyzed by
the GTs starts with the deprotonation of the GlcNAc 4-OH of lipid
II with the active site glutamate of motif 1 acting as the catalytic
base (Terrak et al., 1999; Schwartz et al., 2002). The activated nucle-
ophile then directly attacks the lipid-linked MurNAc carbon C1 of
the growing polysaccharide chain leading to the formation of a new
β-1,4 glycosidic bond and the elongation of the glycan chain. The
GT reaction is complex because the length of the substrate in the
donor site increases by two sugar residues after each catalytic cycle.
In vitro, the processive polymerization of the glycan chain is pre-
ceded by a limiting phase of initiation, probably because lipid II is
not the optimal substrate in the donor site. Using longer oligosac-
charide substrates suppresses this initial lag time (Schwartz et al.,
2002; Wang et al., 2011). Subsequently, chain elongation occurs
in a processive way after each cycle, the lipid-bound glycan chain
product must move to the donor site, probably thanks to the higher
number of interactions that surround the pyrophosphate group
and the sugar moieties in the donor site than in the acceptor site
(Huang et al., 2012). The mechanism by which the product moves
from the acceptor to the donor site, and the factors that determine
the glycan chain length and control its termination remain to be
determined.
GLYCOSYLTRANSFERASE INHIBITORS
Moenomycin is the only natural product known to directly target
the GT active site. In the following sections we will present the
recent advances on GT binders including moenomycin derivatives
and substrate mimics as GT inhibitors.
MOENOMYCIN AND DERIVATIVES
Moenomycin is a natural product isolated from Streptomyces
ghanaensis or bambergiensis (Welzel, 2005). Its structure con-
sists of a pentasaccharide and a chromophore group linked to
a phosphoglycerate-lipid (Figure 3). This structure is reminiscent
of that of the undecaprenyl-linked growing chain (lipid IV) of
PG, the donor substrate. Moenomycin is one of the most active
antibiotics (MIC of 0.05µg/ml for S. aureus) against a variety of
Gram-positive bacteria (10–1000 times better than vancomycin)
and inhibits all the GTs tested at low concentration. Interestingly,
no resistance has been observed, even after moenomycin was used
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FIGURE 2 | Structures of S. aureus MtgA with moenomycin (A) and substrate analog 3 (B) bound in the donor and acceptor sites respectively.The
figures are based on the pdb files 3HZS (A) and 3VMT (B). Moenomycin is shown in yellow and the substrate analog in orange. Hydrogen bonds are shown as
black dotted lines. The backbone atoms of residues 223–227 are shown as sticks to highlight the hydrogen bonds they form with moenomycin.
extensively in animal feed (Butaye et al., 2003). Moenomycin is not
used clinically for the treatment of bacterial infection because of
adverse properties, mainly related to its long lipid tail (Goldman
and Gange, 2000). Since its discovery extensive research has been
performed as it offers a good starting point for the synthesis of new
molecules with better properties. All the available crystal structures
of GTs in complex with moenomycin reveal a similar conforma-
tion of the moenomycin in the donor site (Figure 2A). The sugar
part binds in an extended conformation and interacts with the
GT via many hydrogen bonds with backbone or side chain atoms.
The phosphoglycerate group of moenomycin lies in a positively
charged pocket that probably accommodates the pyrophosphate
group of the growing glycan chain. The two negatively charged
phosphoryl and a carboxylate groups make critical contacts with
conserved residues in this pocket. These interactions orient the
lipid chain toward the hydrophobic groove facing the cytoplasmic
membrane. The lipid group is generally not seen in the crystal
structures.
Structure-activity relationship studies, reviewed by Welzel
(2005), using degradation products of moenomycin or chemically
synthesized fragments showed that the trisaccharide (CEF) and
disaccharide (EF) degradation products inhibit the GT reaction
in vitro, but that only the trisaccharide has an antibacterial activity.
Decreasing the length of the lipid chain leads to a gradual decrease
until a complete loss of antibacterial activity is observed. A struc-
ture of a GT in complex with a neryl-moenomycin has been solved,
showing that this compound is still able to bind to the GT active
site and to inhibit the GT in vitro but it lacks antibacterial activity
(Yuan et al., 2008). Most of the interactions in the carbohydrate
part of moenomycin are mediated by the disaccharide units EF.
The carbamoyl group at C3 of the F-ring and the N -acetyl group
at C2 of the E-ring are critical for binding. The C2-N -acetyl group
of the C-ring also participates in binding and when the C-ring was
replaced by the D-ring, the DEF compound had an antibacterial
activity close to that of the CEF fragment (Yuan et al., 2008), show-
ing that an additional and non-specific bond is sufficient to obtain
antibacterial activity based on EF and a phosphoglycerate-lipid
chain as the core pharmacophores (Welzel, 2005).
On the basis of this knowledge, different groups have tried
to synthesize new analogs with antibacterial activity based on
the EF-phosphoglycerate-lipid fragment of moenomycin (Sofia
et al., 1999; Baizman et al., 2000). Sofia et al. (1999) synthesized a
library of disaccharide analogs to explore modifications at C2 of
the E-ring, at C3 of F-ring, and in the glycerate-lipid part. Some
compounds were 10- to 20-fold more active than the disaccha-
ride derivatives of moenomycin against Gram-positive bacteria
and also showed cell wall inhibition activity (TS30663, Figure 3).
They contained aromatic groups attached to the E and F rings
and a shorter lipid chain of 12 carbons instead of 25. It seems
that the derivatization of the E and F units creates new interac-
tions with the enzyme active site that increase the affinity of the
compounds and probably reduce the effect of the shortening of the
lipid chain. These modifications generated compounds with prop-
erties different from those of the parent molecule and which may
have different modes of action. Using a similar strategy, a diverse
library of compounds has been generated by Alchemia Limited
based on the disaccharide scaffold and where the phosphate group
was replaced by an amide group to increase the stability of the
molecules (ACL19273, Figure 3) (Halliday et al., 2006). A series
of promising active hits have been found but, to the best of our
knowledge, they have not yet reached the clinical trial stage.
SUBSTRATE ANALOGS
Besides moenomycin, which competes for the donor site of the GTs
with the elongating glycan chain, the only known ligand that binds
to the acceptor site of the GTs is the lipid II substrate. Attempts have
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FIGURE 3 | Structures of lipid II, moenomycin, and their analogs.The names of the compounds are as in the original papers and are indicated with the
references.
been made to synthesize GT inhibitors based on monosaccharide
and disaccharide analogs of lipid II, some of them also exhibit-
ing some moenomycin-like features (Hecker et al., 1990; Qiao and
Vederas, 1993; Garneau et al., 2004). Most of the compounds were
not active or were modest inhibitors of the GTs. A monosaccha-
ride analog (compound 5, Figure 3), in which the pyrophosphate
was replaced by a dicarboxylate, exhibited 28% inhibition of the
GTs at 100µM (Garneau et al., 2004). More recently, thanks to the
availability of structural details and a better understanding of the
GT reaction, reports have been published describing the synthesis
and evaluation of new substrate analog inhibitors of the GTs. We
have studied a series of substrate analogs (monosaccharides and
disaccharides) with variations in the lipid, the pyrophosphate, and
the peptide moieties (Dumbre et al., 2012). The peptide moiety
contained 0, 2, or 3 residues of the sequence l-Ala-γ-d-Glu-l-Lys
and the lipid part was a linear 16-carbon chain connected to the
MurNAc via a phosphate or phosphoglycerate group. Although
these compounds had modest GT inhibitory activity (residual
activities between 7 and 84% at a 500µM concentration) they
provided a comprehensive structure-activity view shedding light
on the entities required to design substrate-based inhibitors of
the GTs. The disaccharide analogs were more active than their
cognate monosaccharides. The best compound in the phosphate
series was a disaccharide devoid of a peptide moiety (compound
21 K i= 26µM, Figure 3). The inhibition of GT activity by the
monophosphate analogs decreased as the length of the peptide
increased. Phosphoglycerate compounds were 3- to 10-fold more
efficient than the cognate monophosphate compounds and in this
series the disaccharide dipeptide (compound 62, Figure 3) was
a better inhibitor than compound 21 (K i 17.6 vs. 26µM) with
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a MIC value of 128µg/ml against S. aureus. The substitution of
the C16 lipid chain by geranyl completely abolished the activity of
the compounds. The specificity of these compounds for the donor
and acceptor sites still needs to be determined. Except for com-
pound 62, none of the compounds had antibacterial activity but
the most active ones induced bacterial cell chaining similar to the
phenotype observed with moenomycin (McPherson and Popham,
2003).
Shih et al. (2010) have synthesized lipid I (lipid II without
GlcNAc) and lipid II analogs where the 4-OH of the GlcNAc is
replaced by fluorine so that this compound cannot act as an accep-
tor. These two molecules inhibited the GT activity of E. coli PBP1b
by 13 and 42% at 100µM. The authors also synthesized com-
pounds that mimic the transition state during the sugar transfer
process using an iminocyclitol, a pyrophosphate mimic (a phos-
phono methylserine), and a lipophilic moiety. As for moenomycin,
the lipophilic part was essential for GT inhibition. A compound
with a branched lipid was more potent than a compound with a
linear one. An ether linkage between the pyrophosphate mimic and
the lipophilic moieties was five times more efficient than an amide
linkage. Compound 31 (Figure 3) exhibited the best inhibitory
activity (>80% at 100µM) and an MIC value of 125µM against
S. aureus. This compound showed better inhibition activity of
the GTs than the lipid II analog (lipid II with fluorine instead of
4-OH). The latter can serve as donor substrate and may not be
efficient as an inhibitor.
The same group has synthesized lipid II analogs with variable
peptide moieties and evaluated their binding to the GTs (Shih et al.,
2012). Their results show that the pentapeptide and the tripeptide
derivatives have similar binding affinities; the derivative with an l-
Ala residue has an intermediate affinity. In the absence of peptide
and upon substitution of the d-lactoyl of the MurNAc by a methyl
group no binding was observed. The authors concluded that the
d-lactoyl-l-Ala moiety is essential for substrate binding. We have
shown that lipid II analogs with d-lactoyl have an inhibitory activ-
ity on GTs indicating that the l-Ala residue of these analogs is
not required for binding and that a d-lactoyl group is sufficient
(Dumbre et al., 2012).
Huang et al. (2012) reported the synthesis of lipid II substrate
analogs and their co-crystallization with the MtgA from S. aureus.
In analog 3 (Figure 3), a disaccharide undecaprenyl pyrophos-
phate with a pentapeptide mimic, the 4-OH of GlcNAc has been
inverted (GalNAc) to avoid its utilization as acceptor substrate.
This analog is expected to bind to both sites but, surprisingly,
the crystal structure (pdb 3VMT) of the complex with the MtgA
shows the compound bound to the acceptor site only and not
to the donor site (Figure 2B). This is probably due to the low
binding affinity of lipid II to the donor site and suggests that
a larger oligosaccharide (lipid IV) is probably needed to bind
efficiently to this site. Lipid IV has been found to have a higher
affinity for GT than lipid II (Shih et al., 2011). In the crystal
structure the inhibitor is deeply inserted into the acceptor site,
where the enzyme residues 127–131 are observed in the struc-
ture of the MtgA-moenomycin (3HZS), and this involves a large
displacement of residues 111–131. The peptidic moiety of ana-
log 3 is not seen in the electron density. The pyrophosphate is in
a positively charged pocket comprising residues Arg103, Lys113,
and Arg117. The electron density is unclear and could also be
accounted for by the polypeptidic chain instead of the substrate
analog.
CONCLUSION
Glycosyltransferase is a validated antibacterial target that has not
been fully explored in the past because of technical difficulties
related to the intrinsic properties of the proteins and their sub-
strates. Most of the studies on GT activity inhibition have focused
on moenomycin and its derivatives. The adverse properties of
moenomycin and the need for the lipid moiety to achieve full
antibacterial activity have prevented its development as an antibac-
terial agent in humans. With the ongoing antibiotic resistance
crisis, the GT step in PG synthesis has emerged as one of the major
antibacterial targets for the development of new antibiotics. This
interest has resulted in a major breakthrough in the last decade:
crystal structures of GT and complexes with moenomycin have
been elucidated, the preparation of substrates has been improved,
new assays have been developed, and particularly extensive efforts
in the synthesis of substrate and moenomycin analogs have been
made. Attempts to screen small molecule libraries for GT inhi-
bition have also been investigated. This dynamic will certainly
contribute to our better understanding of the GT-substrate mimic
interactions and the discovery of new small molecule lead com-
pounds. The use of these ligands as templates for the design and
synthesis of new molecules may deliver useful antibacterial drugs
against resistant bacteria.
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